Tiziana Life Sciences Ltd TLSA
Set alert
At close · Oct 30
After hours · Oct 30, 4:07 PM ET
- YTD
- -46.31%
- 1 year
- -56.52%
- Open
- 0.897
- Prev close
- 0.9047
- Mkt cap
- 101.81M
- Vol
- 1.29M
- Avg vol
- 787.75K
- EPS
- -0.21
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.79
- High
- 0.9162
- Forward P/E
- -13.63
- Beta
- 0.18
- Short ratio
- 0.57
- Inst. own
- 1.76%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 9, 2024
- 50-d avg
- 0.9492
- 200-d avg
- 0.86445
- 1y target
- 0.00
News
1 week ago globenewswire.com
Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto
BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its…
2 weeks ago proactiveinvestors.com
Tiziana completes dosing in Phase 2 Alzheimer's trial of intranasal foralumab
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the last patient has begun dosing in its Phase 2 trial of intranasal foralumab in early or mild Alzheimer's disease, with topline data expected in the…
-
2 weeks ago benzinga.com
Tiziana Life Sciences Begins Dosing Last Patient In Its Phase 2 Clinical Trial Evaluating Intranasal Foralumab In Patients With Early/Mild Alzheimer’s Disease; Topline Data Anticipated In Q1 2027
Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal
2 weeks ago globenewswire.com
Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer's Disease
BOSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its…
2 weeks ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares rose 93.3% to $2.03 during Tuesday's pre-market session. The company's market cap stands at $2.6 million. Scinai Immunotherapeutics (NASDAQ:SCNI)…
1 month ago proactiveinvestors.com
Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has asked the US Food and Drug Administration to grant orphan drug designation to its intranasal foralumab for multiple system atrophy (MSA), a rare…
1 month ago proactiveinvestors.com
Tiziana doses first three patients in ALS trial of nasal antibody foralumab
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the first three participants have received their first dose of intranasal foralumab in a Phase 2a trial in people living with amyotrophic lateral…
-
1 month ago benzinga.com
Tiziana Life Sciences Says First Three Participants Receive First Dose Of Intranasal Foralumab In Phase 2a Healey ALS Mymatch BANYAN Clinical Trial
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal
1 month ago proactiveinvestors.com
Tiziana Life Sciences completes patient visits in Phase 2a MS drug trial
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said Monday the last patient has completed their final visit in the company's Phase 2a clinical trial evaluating intranasal foralumab in patients with…
-
1 month ago benzinga.com
Tiziana Completes Phase 2a MS Trial, Topline Data Due In October
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal
1 month ago benzinga.com
Why Is Tiziana Life Sciences Stock Gaining Thursday?
Tiziana Life Sciences (TLSA) stock jumps 21% following an MOU to test intranasal foralumab combo therapy for MS.
1 month ago proactiveinvestors.com
Tiziana Life Sciences partners with Saudi institutions on MS combination therapy trial
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has signed a Memorandum of Understanding with the King Abdullah International Medical Research Center (KAIMRC) and the Foundation for Neurologic Diseases to…
1 month ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Aethlon Medical (NASDAQ:AEMD) shares increased by 382.5% to $6.9 during Thursday's pre-market session. The company's market cap stands at $1.0 million. Akanda (NASDAQ:AKAN) stock rose 15.07%…
1 month ago proactiveinvestors.com
Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration
Tiziana Life Sciences Ltd (NASDAQ:TLSA) was awarded a Buy rating with a $7 price target by BTIG, which pointed to the biotech's approach to modulating central nervous system inflammation as a…
1 month ago proactiveinvestors.com
Dow climbs as stocks rebound on earnings, falling Treasury yields
3:40pm: Small cap wrap Tiziana Life Sciences Ltd (NASDAQ:TLSA) received a Buy rating and $7 price target from BTIG, which highlighted its nasal anti-CD3...
1 month ago benzinga.com
This Occidental Petroleum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Analysts initiated coverage: Neutral COP; Buy TLSA ($7), OXY ($73), NRSN ($8); Sell SM ($35).
-
1 month ago benzinga.com
BTIG Initiates Coverage On Tiziana Life Sciences with Buy Rating, Announces Price Target of $7
BTIG analyst Thomas Shrader initiates coverage on Tiziana Life Sciences (NASDAQ:TLSA) with a Buy rating and announces Price Target of $7.
2 months ago proactiveinvestors.com
Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it will present a poster on its Phase 2a BANYAN clinical trial of intranasal foralumab at ALS Nexus 2026 in Orlando, Florida, on Monday. The…
-
2 months ago benzinga.com
Tiziana Life Sciences To Present Poster, Titled Phase 2a Trial Of Intranasal Foralumab – BANYAN, A Healey ALS MyMatch Trial, At ALS Nexus 2026
Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal
2 months ago globenewswire.com
Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026
BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its…
2 months ago proactiveinvestors.com
Gemini Pro delay leaves Google with an empty flagship tier
Polymarket, the crypto-based prediction platform, puts the probability of no new Gemini Pro release before 30 September at 69%. Every specific launch date...
2 months ago proactiveinvestors.com
Tiziana Life Sciences announces CEO share purchase
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said its CEO Ivor Elrifi increased his stake in the company through the purchase of 321,423 common shares on Nasdaq...
2 months ago globenewswire.com
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its…
3 months ago benzinga.com
Tiziana Life Sciences Says Imaging Results Show Neuroinflammation Reduction in Rare Neurodegenerative Condition
Biotechnology firm Tiziana Life Sciences Ltd. (NASDAQ:TLSA) on Friday revealed promising quantitative PET imaging results from the third patient participating in its Phase 2 clinical trial.
3 months ago benzinga.com
Tiziana Life Sciences Says Imaging Results Show Neuroinflammation Reduction in Rare Neurodegenerative Condition
Tiziana Life Sciences reports reduced brain inflammation in its third Phase 2 trial patient treated with intranasal foralumab for MSA.
3 months ago proactiveinvestors.com
Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported imaging results from the third patient with multiple system atrophy (MSA) to complete dosing in its ongoing Phase 2 clinical trial of intranasal…
-
3 months ago benzinga.com
Tiziana Life Sciences Announces Quantitative PET Imaging Results From Third Patient With Multiple System Atrophy In Its Phase 2 Clinical Trial Treated With Intranasal Foralumab To Complete Dosing; Scans Demonstrated Reductions In Inflammatory Activity
Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces quantitative…
3 months ago globenewswire.com
Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab
BOSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3…
3 months ago proactiveinvestors.com
Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported imaging results from the third patient with multiple system atrophy (MSA) to complete dosing in its...
3 months ago globenewswire.com
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
BOSTON, July 22, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its…
4 months ago proactiveinvestors.com
Qualcomm raises long-term targets as analysts highlight data center, edge AI opportunities
Qualcomm Inc (NASDAQ:QCOM, XETRA:QCI) outlined higher long-term revenue and earnings targets at its investor day, prompting analysts at Bank of America and...
-
4 months ago benzinga.com
Tiziana Announces Last Patient In Ongoing Phase 2a Clinical Trial Receives First Dose Of Intranasal Foralumab For Treatment Of Non-Active Secondary Progressive Multiple Sclerosis; Topline Data Expected In Late Q3/Early Q4 Of 2026
Top line data readout expected in late Q3/early Q4 INFORM-MS trial is a randomized, double-blind, placebo-controlled Phase 2a trial using Intranasal Foralumab in patients with Non-Active Secondary…
-
4 months ago benzinga.com
Tiziana Life Sciences Says Its Executive Chairman And Founder, Gabriele Cerrone, Increases Holdings With Purchase Of 15,000 Common Shares At $1.11 Per Share
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal…
-
5 months ago benzinga.com
Tiziana Life Sciences Completes Enrollment In Phase 2a Trial Of Intranasal Foralumab For Secondary Progressive Multiple Sclerosis, With Topline Data Expected In Q3 2026
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that…
-
5 months ago benzinga.com
Tiziana Life Sciences' Updated Data From Its Ongoing Expanded Access Program Of Intranasal Foralumab For Non-Active Secondary Progressive Multiple Sclerosis Shows Encouraging Trends In Stabilization Of Disability And Meaningful Improvements In Fatigue
Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces updated…
-
5 months ago benzinga.com
Tiziana Life Sciences Announces Initial Quantitative PET Imaging Results From The First Two Patients With Multiple System Atrophy In Its Phase 2 Clinical Trial Of Forlumab
Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces initial…
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
9 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
10 months ago benzinga.com
Why MindWalk Holdings Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
Why MindWalk Holdings Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
2 years ago benzinga.com
Why Tesla Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Why Tesla Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
-
3 years ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
3 years ago benzinga.com
Why PhenomeX Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Novo Integrated Sciences, Inc. (NASDAQ: NVOS) jumped 85.4% to $0.1267 after the company and Farm 7 Group announced a joint venture for Kenya Agricultural Cooperative Project.